Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TCRT | US
-0.10
-4.42%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.16
2.26
2.26
2.11
Alaunos Therapeutics Inc. a clinical-stage oncology-focused cell therapy company develops adoptive TCR engineered T-cell therapies. It develops TCR Library which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS TP53 and EGFR from its TCR library for the treatment of non-small cell lung colorectal endometrial pancreatic ovarian and bile duct cancers; hunTR a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology Inc. and changed its name to Alaunos Therapeutics Inc. in January 2022. Alaunos Therapeutics Inc. was founded in 2003 and is headquartered in Houston Texas.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
103.5%1 month
142.0%3 months
149.3%6 months
132.5%-
-
0.94
-
-
-3.55
724.36
-
-12.58M
3.46M
3.46M
-
-29.15K
-
-
-150.50
4.84
9.48
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.81
Range1M
2.11
Range3M
2.38
Rel. volume
0.23
Price X volume
12.03K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.0322 | 3.80M | -31.78% | n/a | 461.91% |
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Oragenics Inc | OGEN | Biotechnology | 0.345 | 3.63M | 5.83% | n/a | 0.00% |
Virpax Pharmaceuticals Inc | VRPX | Biotechnology | 0.7216 | 3.53M | 6.15% | n/a | 0.00% |
Biodexa Pharmaceticals | BDRX | Biotechnology | 5.98 | 3.47M | 4.91% | n/a | 0.00% |
QNRX | QNRX | Biotechnology | 0.8646 | 3.44M | 1.72% | n/a | 43.11% |
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Aptevo Therapeutics Inc | APVO | Biotechnology | 0.2389 | 3.21M | 20.35% | n/a | 112.59% |
Galera Therapeutics Inc | GRTX | Biotechnology | 0.0555 | 3.07M | 2.78% | n/a | -0.87% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.55 | 0.53 | Cheaper |
Ent. to Revenue | 724.36 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.94 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 149.27 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 3.46M | 3.66B | Emerging |